View the original article here

SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatment-naive HIV patientsLONDON, April 2, 2012 /PRNewswire/ — ViiV Healthcare and Shionogi & Co., Ltd. today announced that initial results have been received from the SPRING-2 (ING113086) Phase III study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1. The study met its primary objective, demonstrating non-inferiority of dolutegravir to raltegravir. Through 48 weeks, 88% of study [...]

- Results published in New England Journal of Medicine showed significantly more patients achieved improvements in skin disease severity scores compared with placebo -INDIANAPOLIS, March 28, 2012 /PRNewswire/ — New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company’s (NYSE: LLY) ixekizumab (pronounced ix” e kiz’ ue mab, previously known as LY2439821), an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, [...]

- Results published in New England Journal of Medicine showed significantly more patients achieved improvements in skin disease severity scores compared with placebo -INDIANAPOLIS, March 28, 2012 /PRNewswire/ — New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company’s (NYSE: LLY) ixekizumab (pronounced ix” e kiz’ ue mab, previously known as LY2439821), an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, [...]

Brodalumab Moving Into Phase 3 for Moderate to Severe PsoriasisTHOUSAND OAKS, Calif., March 28, 2012 /PRNewswire/ — Amgen (NASDAQ: AMGN) announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab (formerly AMG 827) in 198 patients with moderate to severe plaque psoriasis were published in the New England Journal of Medicine. The 12-week, dose-ranging study achieved its primary endpoint with the mean percentage improvement in psoriasis area and severity [...]

FRIDAY March 30, 2012 — People who have experienced recent changes in their health insurance status are more likely to use hospital emergency departments, a new study finds.The use of emergency departments is an important indicator of access to care. People who have difficulty obtaining outpatient care often turn to emergency departments for medical care, said Dr. Adit Ginde, of the University of Colorado School of Medicine, and colleagues.The researchers analyzed data from nearly 160,000 [...]

SUNDAY April 1, 2012 — Several weeks after a study suggested that women who take estrogen-only hormone replacement to treat menopause symptoms may be at lower risk for developing breast cancer, another, much-larger study finds that when used for longer than 10 years, estrogen-only regimens actually raise a woman’s long-term risk for breast cancer.The new study was funded by the National Cancer Institute, part of the U.S. National Institutes of Health, whereas the previous one [...]

MONDAY April 2, 2012 — Alcohol and drug use is common among American teens and more than 15 percent of them meet the criteria for substance abuse, a new study finds.“Once again, we are reminded that in most instances experimentation with alcohol and drugs begins during adolescence,” said Bruce Goldman, director of Substance Abuse Services at The Zucker Hillside Hospital in Glen Oaks, N.Y.“Unfortunately, many youth are at risk of developing abuse and dependency problems [...]

SUNDAY April 1, 2012 — Human papillomavirus infection tends to lasts longer in college-aged black women than whites, possibly setting them up for a higher risk of cervical cancer, according to a new study.The researchers also found that black women are 70 percent more likely to have an abnormal Pap test — the screening for cervical cancer — than their white counterparts. Human papillomavirus, or HPV, which is a sexually transmitted infection, can cause genital [...]

MONDAY April 2, 2012 — Measles vaccines don’t increase the risk of febrile seizures in children ages 4 to 6, according to a new study.Febrile seizures are brief, fever-related convulsions that are not fatal and do not lead to brain damage, epilepsy or other seizure disorders.The study, conducted by the Kaiser Permanente Vaccine Study Center and funded by the U.S. Centers for Disease Control and Prevention, looked at data from nearly 87,000 children ages 48 [...]